1 articulo

Referencias bibliograficas

1. Suberviola B, Castellanos -Ortega A, Gonzalez-Castro A, Garcia-Astudillo LA, Fernandez-

Miret B. Valor Pronostico del aclaramiento de procalcitonina, PCR y leucocitos en el shock
septico. Med Intensiva 2012; 36(3): 177-84. [ Links ]

2. Ruiz-Rodriguez JC, Caballero J, Ruiz-Sanmartin A, Rivas VJ, Perez M, Boveda JL, et al.
Usefulness of procalcitonin clearence as a prognostic biomarker in septic shock. A prospective
pilot study. Med Intensiva 2012; 36 (7): 475-80. [ Links ]

3. Jeong S, Park Y, Cho Y, Kim H. Diagnostic utilities of procalcitonin and C-reactive protein for
the prediction of bacteremia determined by blood culture. Clin Chim Acta 413 (2012): 1731-
6. [ Links ]

4. Gomez B, Bressan S, Mintegi S, Da Dalt L, Blazquez D, Olaciregui I, et al. Diagnostic value

of procalcitonin in well-appearing young febrile infants. Pediatrics 2012; 130(5): 815-
22. [ Links ]

5. Diez-Padrisa N, Bassat Q, Morais L, O'Callaghan-Gordo C, Machevo S, Nhampossa T, et

al. Procalcitonin and Creactive protein as predictors of blood culture positivity among
hospitalised children with severe pneumonia in Mozambique. Trop Med Int Health 2012; 17 (9):
1100-7. [ Links ]

6. Chia-Hung Y, Pei-Shan H, Si-Hue L, Jiunn-Yih W, Shy- Shin C, Kuang-Chau T, et

al. Comparison of the test characteristics of procalcitonin to C-reactive protein and leukocytosis
for the detection of serious bacterial infections in children presenting with fever without source:
A systematic review and meta-analysis. Ann Emerg Med 2012; 60:591-600. [ Links ]

7. Miguel-Bayarri V, Casanoves-Laparra E, Pallas-Beneyto L, Sancho-Chinesta S, Martin-

Osorio L, Tormo-Calandin C, et al. Valor pronostico de los biomarcadores procalcitonina,
interleukina 6 y proteina C reactiva en la sepsis grave. Med Intensiva 2012; 36 (8): 556-
62. [ Links ]

8. Tschaikowsky K, Hedwig-Geissing M, Braun G, Radespiel- Troeger M. Predictive value of

procalcitonina, interleukin- 6, and C-reactive protein for survival in postoperative patiens with
severe sepsis. J Crit Care 2011; 26: 54-64. [ Links ]

9. Lodahl D, Schoder H. Procalcitonin adds to diagnosis, but does not reduce initial antibiotics in
febrile neutropenic chidren. Dan Med Bul 2011; 58 (3): A4233. [ Links ]

10. Bouadma L, Luyt C, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin
to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre
randomised controlled trial. The Lancet 2010; 375: 463-74. [ Links ]

11. Becker KL, Snider R, Nylen ES. Procalcitonin in sepsis and systematic inflammation: a
harmful biomarker and a therapeutic target. Br J Pharmacol 2010; 159: 263-4. [ Links ]

12. Karlsson S, Heikkinen M, Pettila V, Alila S, Vaisanen S, Pulkki K, et al. Predictive value of
procalcitonina decrease in patiens with severe sepsis: a prospective observational study. Crit
Care Med 2010; 14: R205. [ Links ]

13. O'Grady NP, Barie PS, Barret JB, Bleck T, Carroll K, Kalil AC, et al. Guidelines for
evaluation of new fever in critically ill adult patiens: 2008 update from the American College of
Critical Care Medicine and the Infectious Diseases Society of America. Crit Care Med 2008; 36
(4): 1330-49. [ Links ]

14. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M. Procalcitonin
increase in early identification of critically ill patients at high risk of mortality. Crit Care Med
2006; 34: 2596-602. [ Links ]

15. Crist-Crain Mi, Muller B. Procalcitonin in bacterial infections- hype, hope or more or less?
Swiss Med Wkly 2005; 135: 451-60. [ Links ]

16. Crist-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, et al. Effect
of procalcitonin- guided treatment on antibiotic use and outcome in lower respiratory tract
infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363: 600-
7. [ Links ]

17. Crist-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber P, et al. Procalcitonin

Guidance of antibiotic therapy in community-acquired pneumonia: A randomised trial. Am J
Respir Crit Care Med 2005; 174: 84-93. [ Links ]

18. Simon L, Gauvin F, Amre D, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive
protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin
Infect Dis 2004; 39: 206-7. [ Links ]

19. Chiesa C, Pellegrini G, Panero A, Osborn J, Signore F, Assumma M et al. C-reactive

protein, interleukin-6, and procalcitonin in the immediate postnatal period: influence of illness
severity, risk status, antenatal and perinatal complications, and infection. Clin Chem 2003;
49(1): 60-8. [ Links ]

20. Conferencia de Consenso de la American College of Chest Physicians/Society of Critical

Care Medicine. Crit Care Med 1992, 20: 864-74. [ Links ]

Aceptado para su publicación el 3 de junio de 2013

2 articulo
Referencias bibliograficas

1. Largeron M. Amine oxidases of the quinoproteins family: their implication in the metabolic
oxidation of xenobiotics. Pharm Fr 2011; 69 (1): 53-61. [ Links ]

2. Vitale AA, Ciprian-Ollivier JO, Vitale MG, Romero E, Pomilio AB. Estudio clinico de
marcadores de la hipermetilacion indolica en las alteraciones de la percepcion. Acta Bioquim
Clin Latinoam 2010; 44 (4): 627-42.

3. Pomilio AB, Ciprian Ollivier JO, Vitale AA. Flavoproteinas que actuan como amino-oxidasas:
Estructura, funcion e importancia clinica. Acta Bioquim Clin Latinoam 2013; 47: 279-305.

4. Smith-Mungo LI, Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in
biology. Matrix Biol 1998; 16 (7): 387-98.

5. Uscn Life Science Inc. Lysyl osidase (LOX). Disponible en: www.uscnk.com/directory/Lysyl-
oxidase(LOX)-2580.htm. (Fecha de acceso: mayo 2013).

6. Khan S, Chatra L, Prashanth SK, Veena KM, Rao PK. Pathogenesis of oral submucous
fibrosis. J Cancer Res Ther 2012; 8 (2): 199-203.
7. Cox TR, Bird D, Baker AM, Barker HE, Ho MW, Lang G, et al. LOX-mediated collagen
crosslinking is responsible for fibrosis-enhanced metastasis. Cancer Res 2013; 73 (6): 1721-32.

8. Cosimo QC, Daniela L, Elsa B, Carlo DV, Giuseppe F. Kinky hair, kinky vessels, and bladder
diverticula in Menkes disease. J Neuroimaging 2011; 21 (2): e114-6.

9. Mizuno S, Yasuo M, Bogaard HJ, Kraskauskas D, Alhussaini A, Gomez-Arroyo J, et al.

Copper deficiency induced emphysema is associated with focal adhesion kinase inactivation.
PLoS One 2012; 7 (1): e30678.

10. Kohno T, Urao N, Ashino T, Sudhahar V, McKinney RD, Hamakubo T, et al. Novel role of
copper transport protein antioxidant-1 in neointimal formation after vascular injury. Arterioscler
Thromb Vasc Biol 2013; 33 (4): 805-13.

11. Hasan NM, Lutsenko S. Regulation of copper transporters in human cells. Curr Top Membr
2012; 69: 137-61.

12. National Center for Biotechnology Information, Lysyl Oxidase (LOX). Disponible
en: www.ncbi.nlm.nih.gov/gene (search: lysyl oxidase). (Fecha de acceso: mayo 2013).

13. Huang Y, Dai J, Tang R, Zhao W, Zhou Z, Wang W, et al. Cloning and characterization of a
human lysyl oxidase-like 3 gene (hLOXL3). Matrix Biol 2001; 20 (2): 153-7.

14. Maki JM, Kivirikko KI. Cloning and characterization of a fourth human lysyl oxidase
isoenzyme. Biochem J 2001; 355: 381-7.

15. Maki JM, Tikkanen H, Kivirikko KI. Cloning and characterization of a fifth human lysyl
oxidase isoenzyme: the third member of the lysyl oxidase-related subfamily with four scavenger
receptor cysteine-rich domains. Matrix Biol 2001; 20 (7): 493-6.

16. Maki J. Cloning and characterization of the fourth and the fifth human lysyl oxidase
isoenzymes, and the consequences of a targeted inactivation of the first described lysyl oxidase
isoenzyme in mice. Academic Dissertation, Faculty of Medicine, University of Oulu, Department
of Medical Biochemistry, Finlandia; 2002. Disponible
en: www.herkules.oulu.fi/isbn9514267397/isbn 9514267397.pdf. (Fecha de acceso: mayo
2013).

17. Herranz N, Dave N, Millanes-Romero A, Morey L, Diaz VM, Lorenz-Fonfria V, et al. Lysyl
oxidase-like 2 deaminates lysine 4 in histone H3. Mol Cell 2012; 46 (3): 369-76.

18. Semenza GL. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells.
Trends Mol Med 2012; 18 (9): 534-43.

19. Tadmor T, Bejar J, Attias D, Mischenko E, Sabo E, Neufeld G, et al. The expression of lysyl-
oxidase gene family members in myeloproliferative neoplasms. Am J Hematol 2013; 88 (5):
355-8.

20. Nishioka T, Eustace A, West C. Lysyl oxidase: from basic science to future cancer
treatment. Cell Struct Funct 2012; 37 (1): 75-80.

21. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. Nature
Rev Cancer 2012; 12 (8): 540-52.

22. Thomas C, Karnoub AE. Lysyl oxidase at the crossroads of mesenchymal stem cells and
epithelial-mesenchymal transition. Oncotarget 2013; 4 (3): 376-7.

23. Seton-Rogers S. Metastasis: dynamic interactions. Nat Rev Cancer 2012; 12 (6): 378.
24. Csiszar K. Lysyl oxidases: a novel multifunctional amine oxidase family. Prog Nucleic Acid
Res Mol Biol 2001; 70: 1-32.

25. Alberts B. Molecular biology of the cell. New York: Garland Science; 2002.

26. Siegel RC, Fu JC, Uto N, Horiuchi K, Fujimoto D. Collagen cross-linking: lysyl oxidase
dependent synthesis of pyridinoline in vitro: confirmation that pyridinoline is derived from
collagen. Biochem Biophys Res Commun 1982; 108 (4): 1546-50.

27. Kielty CM, Sherratt MJ, Shuttleworth CA. Elastic fibers. J Cell Sci 2002; 115 (14): 2817-28.

28. Fong SFT, Fong KSK, Csiszar K. LOX (lysyl oxidase). Atlas Genet Cytogenet Oncol
Haematol; February 2009. Disponible
en: http://AtlasGeneticsOncology.org/Genes/LOXID41191ch5q23.html. (Fecha de acceso:
mayo 2013).

29. Langton AK, Griffiths CE, Sherratt MJ, Watson RE. Crosslinking of structural proteins in
ageing skin: an in situ assay for the detection of amine oxidase activity. Biogerontology 2013;
14 (1): 89-97.

30. Molnar J, Fong KS, He QP, Hayashi K, Kim Y, Fong SF, et al. Structural and functional
diversity of lysyl oxidase and the LOX-like proteins. Biochim Biophys Acta 2003; 1647 (1-2):
220-4.

31. Liu X, Zhao Y, Gao J, Pawlyk B, Starcher B, Spencer JA, et al. Elastic fiber homeostasis
requires lysyl oxidase-like 1 protein. Nat Genet 2004; 36 (2): 178-82.

32. Uscn Life Science Inc. Lysyl Oxidase Like Protein 1 (LOX1). Disponible
en: www.uscnk.com/img/Lysyl-Oxidase-Like-Protein-1-(LOXL1)-95551.jpg. (Fecha de acceso:
mayo 2013).

33. Kasım B, Irkec M, Alikas Alikaşifoğlu fiifoglu M, Orhan M, Mocan MC, Aktaş D. Association
of LOXL1 gene polymorphisms with exfoliation syndrome/glaucoma and primary open angle
glaucoma in a Turkish population. Mol Vis 2013; 19: 114-20.

34. Jourdan-Le Saux C, Le Saux O, Donlon T, Boyd CD, Csiszar K. The human lysyl oxidase-
related gene (LOXL2) maps between markers D8S280 and D8S278 on chromosome 8p21.2-
p21.3. Genomics 1998; 51 (2): 305-7.

35. Uscn Life Science Inc. Lysyl Oxidase Like Protein 2 (LOX2). Disponible
en: www.uscnk.com/directory/Lysyl-Oxidase-Like-2(LOXL2)-5552.htm. Lysyl Oxidase Like
Protein 2 (LOXL2). (Fecha de acceso: mayo 2013).

36. Cano A, Santamaria PG, Moreno-Bueno G. LOXL2 in epithelial cell plasticity and tumor
progression. Future Oncol 2012; 8(9): 1095-108.

37. Uscn Life Science Inc. Lysyl Oxidase Like Protein 3 (LOX3). Disponible
en: www.uscnk.com/directory/Lysyl-Oxidase-Like-3(LOXL3)-5553.htm. Lysyl Oxidase Like
Protein 3 (LOXL3). (Fecha de acceso: mayo 2013).

38. Uscn Life Science Inc. Lysyl Oxidase Like Protein 4 (LOX4). Disponible
en: www.uscnk.com/directory/Lysyl-Oxidase-Like-4(LOXL4)-5554.htm. Lysyl Oxidase Like
Protein 4 (LOXL4). (Fecha de acceso: mayo 2013).

39. Jourdan-Le Saux C, Tomsche A, Ujfalusi A, Jia L, Csiszar K. Central nervous system,
uterus, heart, and leukocyte expression of the LOXL3 gene, encoding a novel lysyl oxidase-like
protein. Genomics 2001; 74 (2): 211-8.
40. Ito H, Akiyama H, Iguchi H, Iyama K, Miyamoto M, Ohsawa K. Molecular cloning and
biological activity of a novel lysyl oxidase-related gene expressed in cartilage. J Biol Chem
2001; 276 (26): 24023-9.

41. Busnadiego O, Gonzalez-Santamaria J, Lagares D, Guinea- Viniegra J, Pichol-Thievend C,

Muller L, et al. LOXL4 is induced by TGF-â1 through Smad and JunB/Fra2 and contributes to
vascular matrix remodeling. Mol Cell Biol 2013 Apr 9.[Epub ahead of print].

42. Science Photo Library. Lysyl oxidase enzyime molecule. Disponible

en: www.sciencephoto.com/media/88619/view. Lysyl oxidase enzyme molecule. (Fecha de
acceso: mayo 2013).

43. Kagan HM. Characterization and regulation of lysyl oxidase. En: Mecham RP, editor.
Biology of Extracellular Matrix. Orlando: Academic Press; 1986. p. 321-89.

44. Stassen FL. Properties of highly purified lysyl oxidase from embryonic chick cartilage.
Biochim Biophys Acta 1976; 438 (1): 49-60.

45. Kuivaniemi H, Savolainen ER, Kivirikko KI. Human placental lysyl oxidase. Purification,
partial characterization, and preparation of two specific antisera to the enzyme. J Biol Chem
1984; 259 (11): 6996-7002.

46. Cronlund AL, Kagan HM. Comparison of lysyl oxidase from bovine lung and aorta. Connect
Tissue Res 1986; 15 (3): 173-85.

47. Shackleton DR, Hulmes DJ. Purification of lysyl oxidase from piglet skin by selective
interaction with Sephacryl S-200. Biochem J 1990; 266 (3): 917-9.

48. Trackman PC, Pratt AM, Wolanski A, Tang SS, Offner GD, Troxler RF, et al. Cloning of rat
aorta lysyl oxidase cDNA: complete codons and predicted amino acid sequence. Biochemistry
1990; 29 (20): 4863-70.

49. Trackman PC, Pratt AM, Wolanski A, Tang SS, Offner GD, Troxler RF, et al. Cloning of rat
aorta lysyl oxidase cDNA: complete codons and predicted amino acid sequence. Erratum.
Biochemistry 1991; 30 (33): 8282.

50. Hamalainen ER, Jones TA, Sheer D, Taskinen K, Pihlajaniemi T, Kivirikko KI. Molecular
cloning of human lysyl oxidase and assignment of the gene to chromosome 5q23.3-31.2.
Genomics 1991; 11 (3): 508-16.

51. Hamalainen ER, Kemppainen R, Pihlajaniemi T, Kivirikko KI. Structure of the human lysyl
oxidase gene. Genomics 1993; 17 (3): 544-8.

52. Mariani TJ, Trackman PC, Kagan HM, Eddy RL, Shows TB, Boyd CD, et al. The complete
derived amino acid sequence of human lysyl oxidase and assignment of the gene to
chromosome 5 (extensive sequence homology with the murine ras recision gene). Matrix 1992;
12 (3): 242-8.

53. Wu Y, Rich CB, Lincecum J, Trackman PC, Kagan HM, Foster JA. Characterization and
developmental expression of chick aortic lysyl oxidase. J Biol Chem 1992; 267 (34): 24199-206.

54. Contente S, Csiszar K, Kenyon K, Friedman RM. Structure of the mouse lysyl oxidase gene.
Genomics 1993; 16 (2): 395-400.

55. Boyd CD, Mariani TJ, Kim Y, Csiszar K. The size heterogeneity of human lysyl oxidase
mRNA is due to alternate polyadenylation site and not alternate exon usage. Mol Biol Rep 1995;
21 (2): 95-103.
56. Peltonen L, Kuivaniemi H, Palotie A, Horn N, Kaitila I, Kivirikko KI. Alterations in copper and
collagen metabolism in the Menkes syndrome and a new subtype of the Ehlers-Danlos
syndrome. Biochemistry 1983; 22 (26): 6156-63.

57. Kuivaniemi H, Ala-Kokko L, Kivirikko KI. Secretion of lysyl oxidase by cultured human skin
fibroblasts and effects of monensin, nigericin, tunicamycin and colchicine. Biochim Biophys Acta
1986; 883 (2): 326-34.

58. Trackman PC, Bedell-Hogan D, Tang J, Kagan HM. Post-translational glycosylation and
proteolytic processing of a lysyl oxidase precursor. J Biol Chem 1992; 267 (12): 8666-71.

59. Cronshaw AD, Fothergill-Gilmore LA, Hulmes DJ. The proteolytic processing site of the
precursor of lysyl oxidase. Biochem J 1995; 306 (Pt 1): 279-84.

60. Panchenko MV, Stetler-Stevenson WG, Trubetskoy OV, Gacheru SN, Kagan HM.
Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase.
Potential role of procollagen C-proteinase. J Biol Chem 1996; 271 (12): 7113-9.

61. Takahara K, Lyons GE, Greenspan DS. Bone morphogenetic protein-1 and a mammalian
tolloid homologue (mTld) are encoded by alternatively spliced transcripts which are differentially
expressed in some tissues. J Biol Chem 1994; 269 (51): 32572-8.

62. Uzel MI, Scott IC, Babakhanlou-Chase H, Palamakumbura AH, Pappano WN, Hong HH, et
al. Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-
lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse
embryo fibroblast cultures. J Biol Chem 2001; 276 (25): 22537-43.

63. Uzel MI, Shih SD, Gross H, Kessler E, Gerstenfeld LC, Trackman PC. Molecular events that
contribute to lysyl oxidase enzyme activity and insoluble collagen accumulation in
osteosarcoma cell clones. J Bone Miner Res 2000; 15 (6): 1189-97.

64. Atsawasuwan P, Mochida Y, Katafuchi M, Tokutomi K, Mocanu V, Parker CE, et al. A novel
proteolytic processing of prolysyl oxidase. Connect Tissue Res 2011; 52 (6): 479-86.

65. Gacheru SN, Trackman PC, Shah MA, O'Gara CY, Spacciapoli P, Greenaway FT, et al.
Structural and catalytic properties of copper in lysyl oxidase. J Biol Chem 1990; 265 (31):
19022-7.

66. Krebs CJ, Krawetz SA. Lysyl oxidase copper-talon complex: a model. Biochim Biophys Acta
1993; 1202 (1): 7-12.

67. Kagan HM. Lysyl oxidase: mechanism, regulation and relationship to liver fibrosis. Pathol
Res Pract 1994; 190 (9-10): 910-9.

68. Rucker RB, Kosonen T, Clegg MS, Mitchell AE, Rucker BR, Uriu-Hare JY, et al. Copper,
lysyl oxidase, and extracellular matrix protein cross-linking. Am J Clin Nutr 1998; 67 (5): 996-
1002.

69. Tang C, Klinman JP. The catalytic function of bovine lysyl oxidase in the absence of copper.
J Biol Chem 2001; 276 (33): 30575-8.

70. Williamson PR, Kagan HM. Reaction pathway of bovine aortic lysyl oxidase. J Biol Chem
1986; 261 (20): 9477-82.

71. Williamson PR, Kagan HM. a-Proton abstraction and carbanion formation in the mechanism
of action of lysyl oxidase. J Biol Chem 1987; 262 (17): 8196-201.
72. Gacheru SN, Trackman PC, Kagan HM. Evidence for a functional role for histidine in lysyl
oxidase catalysis. J Biol Chem 1988; 263 (32): 16704-8.

73. Shah MA, Scaman CH, Palcic MM, Kagan HM. Kinetics and stereospecificity of the lysyl
oxidase reaction. J Biol Chem 1993; 268 (16): 11573-9.

74. Akagawa M, Suyama K. Characterization of a model compound for the lysine tyrosylquinone
cofactor of lysyl oxidase. Biochem Biophys Res Commun 2001; 281 (1): 193-9.

75. Wilmarth KR, Froines JR. In vitro and in vivo inhibition of lysyl oxidase by
aminopropionitriles. J Toxicol Environ Health 1992; 37 (3): 411-23.

76. Dawson DA, Rinaldi AC, Poch G. Biochemical and toxicological evaluation of agent-cofactor
reactivity as a mechanism of action for osteolathyrism. Toxicology 2002; 177 (2-3): 267-84.

77. Narayanan AS, Siegel RC, Martin GR. On the inhibition of lysyl oxidase by b-
aminopropionitrile. Biochem Biophys Res Commun 1972; 46: 745-51.

78. Tang SS, Trackman PC, Kagan HM. Reaction of aortic lysyl oxidase with b-
aminopropionitrile. J Biol Chem 1983; 258 (7): 4331-8.

79. Gacheru SN, Trackman PC, Calaman SD, Greenaway FT, Kagan HM. Vicinal diamines as
pyrroloquinoline quinone-directed irreversible inhibitors of lysyl oxidase. J Biol Chem 1989; 264
(22): 12963-9.

80. Williamson PR, Kagan HM. Electronegativity of aromatic amines as a basis for the
development of ground state inhibitors of lysyl oxidase. J Biol Chem 1987; 262 (30): 14520-4.

81. Gavriel P, Kagan HM. Inhibition by heparin of the oxidation of lysine in collagen by lysyl
oxidase. Biochemistry 1988; 27 (8): 2811-5.

82. Nagan N, Callery PS, Kagan HM. Aminoalkylaziridines as substrates and inhibitors of lysyl
oxidase: specific inactivation of the enzyme by N-(5-aminopentyl)aziridine. Front Biosci 1998; 3:
A23-6.

83. Shah MA, Trackman PC, Gallop PM, Kagan HM. Reaction of lysyl oxidase with trans-2-
phenyl-cyclopropylamine. J Biol Chem 1993; 268 (16): 11580-5.

84. Liu G, Nellaiappan K, Kagan HM. Irreversible inhibition of lysyl oxidase by homocysteine
thiolactone and its selenium and oxygen analogues. Implications for homocystinuria. J Biol
Chem 1997; 272 (51): 32370-7.

85. Peyrol S, Raccurt M, Gerard F, Gleyzal C, Grimaud JA, Sommer P. Lysyl oxidase gene
expression in the stromal reaction to in situ and invasive ductal breast carcinoma. Am J Pathol
1997; 150 (2): 497-507.

86. Fujimaki T, Hotta Y, Sakuma H, Fujiki K, Kanai A. Large-scale sequencing of the rabbit
corneal endothelial cDNA library. Cornea 1999; 18 (1): 109-14.

87. Gregory KE, Marsden ME, Anderson-MacKenzie J, Bard JB, Bruckner P, Farjanel J, et al.
Abnormal collagen assembly, though normal phenotype, in alginate bead cultures of chick
embryo chondrocytes. Exp Cell Res 1999; 246 (1): 98-107.

88. Di Donato A, Ghiggeri GM, Di Duca M, Jivotenko E, Acinni R, Campolo J, et al. Lysyl
oxidase expression and collagen cross-linking during chronic adriamycin nephropathy. Nephron
1997; 76 (2): 192-200.
89. Hayashi K, Fong KS, Mercier F, Boyd CD, Csiszar K, Hayashi M. Comparative
immunocytochemical localization of lysyl oxidase (LOX) and the lysyl oxidase-like (LOXL)
proteins: changes in the expression of LOXL during development and growth of mouse tissues.
J Mol Histol 2004; 35 (8-9): 845-55.

90. Coral K, Angayarkanni N, Madhavan J, Bharathselvi M, Ramakrishnan S, Nandi K, et al.

Lysyl oxidase activity in the ocular tissues and the role of LOX in proliferative diabetic
retinopathy and rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci 2008; 49 (11):
4746-52.

91. Laczko R, Szauter KM, Jansen MK, Hollosi P, Muranyi M, Molnar J, et al. Active lysyl
oxidase (LOX) correlates with focal adhesion kinase (FAK)/paxillin activation and migration in
invasive astrocytes. Neuropathol Appl Neurobiol 2007; 33 (6): 631-43.

92. Dalmay T, Edwards DR. MicroRNAs and the hallmarks of cancer. Oncogene 2006; 25 (46):
6170-5.

93. Franklin TJ. Current approaches to the therapy of fibrotic diseases. Biochem Pharmacol
1995; 49 (3): 267-73.

94. Franklin TJ. Therapeutic approaches to organ fibrosis. Int J Biochem Cell Biol 1997; 29 (1):
79-89.

95. Myllyharju J, Kivirikko KI. Collagens and collagen-related diseases. Ann Med 2001; 33 (1):
7-21.

96. Konishi A, Iguchi H, Ochi J, Kinoshita R, Miura K, Uchino H. Increased lysyl oxidase activity
in culture medium of nonparenchymal cells from fibrotic livers. Gastroenterology 1985; 89 (4):
709-15.

97. Murawaki Y, Kusakabe Y, Hirayama C. Serum lysyl oxidase activity in chronic liver disease
in comparison with serum levels of prolyl hydroxylase and laminin. Hepatology 1991; 14 (6):
1167-73.

98. Wakasaki H, Ooshima A. Immunohistochemical localization of lysyl oxidase with monoclonal

antibodies. Lab Invest 1990; 63 (3): 377-84.

99. Li W, Nellaiappan K, Strassmaier T, Graham L, Thomas KM, Kagan HM. Localization and
activity of lysyl oxidase within nuclei of fibrogenic cells. Proc Natl Acad Sci USA 1997; 94 (24):
12817-22.

100. Sharma R, Kramer JA, Krawetz SA. Lysyl oxidase, cellular senescence and tumor
suppression. Biosci Rep 1997; 17 (4): 409-14.

101. Kim Y, Peyrol S, So CK, Boyd CD, Csiszar K. Coexpression of the lysyl oxidase-like gene
(LOXL) and the gene encoding type III procollagen in induced liver fibrosis. J Cell Biochem
1999; 72 (2): 181-8.

102. Giampuzzi M, Botti G, Cilli M, Gusmano R, Borel A, Sommer P, et al. Downregulation of

lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive
activation of ras protooncogene. J Biol Chem 2001; 276 (31): 29226-32.

103. Sommer P, Gleyzal C, Raccurt M, Delbourg M, Serrar M, Joazeiro P, et al. Transient

expression of lysyl oxidase by liver myofibroblasts in murine schistosomiasis. Lab Invest 1993;
69 (4): 460-70.
104. Yamaguchi Y, Takihara T, Chambers RA, Veraldi KL, Larregina AT, Feghali-Bostwick CA.
A peptide derived from endostatin ameliorates organ fibrosis. Sci Transl Med 2012; 4 (136):
136ra71.

105. Feres-Filho EJ, Menassa GB, Trackman PC. Regulation of lysyl oxidase by basic fibroblast
growth factor in osteoblastic MC3T3-E1 cells. J Biol Chem 1996; 271 (11): 6411-6.

106. Trackman PC, Graham RJ, Bittner HK, Carnes DL, Gilles JA, Graves DT. Inflammation-
associated lysyl oxidase protein expression in vivo, and modulation by FGF-2 plus IGF-1.
Histochem Cell Biol 1998; 110 (1): 9-14.

107. Green RS, Lieb ME, Weintraub AS, Gacheru SN, Rosenfield CL, Shah S, et al.
Identification of lysyl oxidase and other platelet-derived growth factor-inducible genes in
vascular smooth muscle cells by differential screening. Lab Invest 1995; 73 (4): 476-82.

108. Gacheru SN, Thomas KM, Murray SA, Csiszar K, Smith- Mungo LI, Kagan HM.
Transcriptional and post-transcriptional control of lysyl oxidase expression in vascular smooth
muscle cells: effects of TGF-beta1 and serum deprivation. J Cell Biochem 1997; 65 (3): 395-
407.

109. Shanley CJ, Gharaee-Kermani M, Sarkar R, Welling TH, Kriegel A, Ford JW, et al.
Transforming growth factor-beta1 increases lysyl oxidase enzyme activity and mRNA in rat
aortic smooth muscle cells. J Vasc Surg 1997; 25 (3): 446-52.

110. Hong HH, Uzel MI, Duan C, Sheff MC, Trackman PC. Regulation of lysyl oxidase,
collagen, and connective tissue growth factor by TGF-beta1 and detection in human gingiva.
Lab Invest 1999; 79 (12): 1655-67.

111. Bose KK, Chakraborty J, Khuder S, Smith-Mensah WH, Robinson J. Lysyl oxidase activity
in the cells of flexor retinaculum of individuals with carpal tunnel syndrome. J Occup Environ
Med 2000; 42 (6): 582-7.

112. Bronson RE, Calaman SD, Traish AM, Kagan HM. Stimulation of lysyl oxidase
(EC 1.4.3.13) activity by testosterone and characterization of androgen receptors in cultured calf
aorta smooth-muscle cells. Biochem J 1987; 244 (2): 317-23.

113. Choung J, Taylor L, Thomas K, Zhou X, Kagan H, Yang X, et al. Role of EP2 receptors
and cAMP in prostaglandin E2 regulated expression of type I collagen alpha1, lysyl oxidase,
and cyclooxygenase-1 genes in human embryo lung fibroblasts. J Cell Biochem 1998; 71 (2):
254-63.

114. Tan RS, Taniguchi T, Harada H. Identification of the lysyl oxidase gene as target of the
antioncogenic transcription factor, IRF-1, and its possible role in tumor suppression. Cancer
Res 1996; 56 (10): 2417-21.

115. Di Donato A, Lacal JC, Di Duca M, Giampuzzi M, Ghiggeri G, Gusmano R. Microinjection

of recombinant lysyl oxidase blocks oncogenic p21-Ha-Ras and progesterone effects
on Xenopus laevis oocyte maturation. FEBS Lett 1997; 419 (1): 63-8.

116. Ravid K, Smith-Mungo LI, Zhao Z, Thomas KM, Kagan HM. Upregulation of lysyl oxidase
in vascular smooth muscle cells by cAMP: role for adenosine receptor activation. J Cell
Biochem 1999; 75 (1): 177-85.

117. Slee RB, Hillier SG, Largue P, Harlow CR, Miele G, Clinton M. Differentiation-dependent
expression of connective tissue growth factor and lysyl oxidase messenger ribonucleic acids in
rat granulosa cells. Endocrinology 2001; 142 (3): 1082-9.
118. Harlow CR, Rae M, Davidson L, Trackman PC, Hillier SG. Lysyl oxidase gene expression
and enzyme activity in the rat ovary: regulation by follicle-stimulating hormone, androgen, and
transforming growth factor-beta superfamily members in vitro. Endocrinology 2003; 144(1): 154-
62.

119. Omori K, Fujiseki Y, Omori K, Suzukawa J, Inagaki C. Regulation of the expression of lysyl
oxidase mRNA in cultured rabbit retinal pigment epithelium cells. Matrix Biol 2002; 21 (4): 337-
48.

120. Zhang D, Simmen RC, Michel FJ, Zhao G, Vale-Cruz D, Simmen FA. Secretory leukocyte
protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and
negative regulation of growth-associated genes. J Biol Chem 2002; 277 (33): 29999-30009.

121. Rae MT, Niven D, Ross A, Forster T, Lathe R, Critchley HO, et al. Steroid signalling in
human ovarian surface epithelial cells: the response to interleukin-1alpha determined by
microarray analysis. J Endocrinol 2004; 183 (1): 19-28.

122. Chen LJ, Zhao Y, Gao S, Chou IN, Toselli P, Stone P, et al. Downregulation of lysyl
oxidase and upregulation of cellular thiols in rat fetal lung fibroblasts treated with cigarette
smoke condensate. Toxicol Sci 2005; 83 (2): 372-9.

123. Gao S, Chen K, Zhao Y, Rich CB, Chen L, Li SJ, et al. Transcriptional and
posttranscriptional inhibition of lysyl oxidase expression by cigarette smoke condensate in
cultured rat fetal lung fibroblasts. Toxicol Sci 2005; 87 (1): 197-203.

124. Rodriguez C, Alcudia JF, Martinez-Gonzalez J, Raposo B, Navarro MA, Badimon L. Lysyl
oxidase (LOX) downregulation by TNFalpha: a new mechanism underlying TNFalpha-induced
endothelial dysfunction. Atherosclerosis 2008; 196 (2): 558-64.

125. Weissen-Plenz G, Eschert H, Volker W, Sindermann JR, Beissert S, Robenek H, et al.

Granulocyte macrophage colony-stimulating factor deficiency affects vascular elastin production
and integrity of elastic lamellae. J Vasc Res 2008; 45 (2): 103-10.

126. Kothapalli CR, Ramamurthi A. Benefits of concurrent delivery of hyaluronan and IGF-1
cues to regeneration of crosslinked elastin matrices by adult rat vascular cells. J Tissue Eng
Regen Med 2008; 2 (2-3): 106-16.

127. Lowry MB, Lotinun S, Leontovich AA, Zhang M, Maran A, Shogren KL, et al. Osteitis
fibrosa is mediated by plateletderived growth factor-A via a phosphoinositide 3-
kinasedependent signaling pathway in a rat model for chronic hyperparathyroidism.
Endocrinology 2008; 149 (11): 5735-46.

128. Song YL, Ford JW, Gordon D, Shanley CJ. Regulation of lysyl oxidase by interferon-
gamma in rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2000; 20 (4): 982-8.

129. Li W, Chou IN, Boak A, Kagan HM. Downregulation of lysyl oxidase in cadmium-resistant
fibroblasts. Am J Respir Cell Mol Biol 1995; 13 (4): 418-25.

130. Yeowell HN, Marshall MK, Walker LC, Ha V, Pinnell SR. Regulation of lysyl oxidase mRNA
in dermal fibroblasts from normal donors and patients with inherited connective tissue disorders.
Arch Biochem Biophys 1994; 308 (1): 299-305.

131. Chinoy MR, Zgleszewski SE, Cilley RE, Krummel TM. Dexamethasone enhances ras-
recision gene expression in cultured murine fetal lungs: role in development. Am J Physiol Lung
Cell Mol Physiol 2000; 279 (2): L312-8.
132. Dimaculangan DD, Chawla A, Boak A, Kagan HM, Lazar MA. Retinoic acid prevents
downregulation of ras recision gene/lysyl oxidase early in adipocyte differentiation.
Differentiation 1994; 58 (1): 47-52.

133. Chambers RC, Laurent GJ. The Lung. En: Comper WD, editor. Extracellular Matrix. Vol. 1.
Amsterdam: Harvood Academic Publishers; 1996. p. 378-409.

134. Wight TN. Arterial wall. En: Comper WD, editor. Extracellular Matrix. Vol. 1. Amsterdam:
Harvood Academic Publishers; 1996. p. 175-202.

135. Cleary EG, Gibson MA. Elastic tissue, elastin and associated microfibrils. En: Comper WD,
editor. Extracellular Matrix. Vol. 1. Amsterdam: Harvood Academic Publishers; 1996. p. 95-140.

136. Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, et al. A
molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 2002; 62 (15): 4478-83.

137. Aydin S, Signorelli S, Lechleitner T, Joannidis M, Pleban C, Perco P, et al. Influence of

microvascular endothelial cells on transcriptional regulation of proximal tubular epithelial cells.
Am J Physiol Cell Physiol 2008; 294 (2): C543-54.

138. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, et al. Lysyl oxidase is
essential for hypoxia-induced metastasis. Nature 2006; 440 (7088): 1222-6.

139. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, et al. Hypoxia
promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J
Clin Invest 2007; 117 (12): 3810-20.

140. Sorensen BS, Alsner J, Overgaard J, Horsman MR. Hypoxia induced expression of
endogenous markers in vitro is highly influenced by pH. Radiother Oncol 2007; 83 (3): 362-6.

141. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates
hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 2008; 105 (17):
6392-7.

Aceptado para su publicación el 24 de mayo de 2013

3 articulo
Referencias bibliográficas

1. Hamid A, Nissar AW, Jyotdeep K. New perspectives on folate transport in relation to

alcoholism–induced folate malabsortion. Association with epigenome stability and cancer
development. Febs J 2009. Publicado en línea 23 de marzo de 2009; Disponible
en: http//onlinelibrary.wiley.com/doi/10.1111/j.1742-4658.2009.06959.x/full.

2. Kräuler B. Biochemistry of B12-cofactors in human metabolism. Subcell Biochem 2012; 56:

323-46. [ Links ]

3. Fedosov SN. Physiological and molecular aspects of cobalamin transport. Subcell Biochem
2012; 56: 347-67. [ Links ]

4. Oberley MJ, Yang DT. Laboratory testing for cobalamin deficiency in megaloblastic anemia.
Am J Hematol 2013 Jun; 88 (6): 522-6. [ Links ]
5. Huges CF, Ward M, Hoey L, McNulty H. Vitamin B12 and ageing: current issues and
interaction with folate. Ann Clin Biochem 2013 Jul; 50 (Pt.4): 315-29. [ Links ]

6. Green R, Dwyre DM. Evaluation of macrocitic anemias Semin Hematol Oct 2015; 52 (4): 279-
86. [ Links ]

7. Wickramasinghe SN. Diagnosis of megaloblastic anaemias. Blood Rev 2006; 20: 299-
318. [ Links ]

8. Hesdorffer CS, Longo DL. Drug-induced megaloblastic anemia. New Eng J Med 2015; 373:
1649-58. [ Links ]

9. Zelder F, Sonnay M, Prieto L. Antivitamins for medicinal applications. Chem Bio Chem 2015;
16: 1264-78. [ Links ]

10. Devalia V, Hamilton MS, Molloy AM. Guidelines for the diagnosis of cobalamin and folate
disorders. Br J Haematol 2014 Aug; 166 (4): 496-513. [ Links ]

11. Stabler SP, Macell PD, Podell EI, Allen RH, Lindenbaum J. Assay of methylmalonic acid in
the serum of patients with cobalamin deficiency using capillary gas chromatography-mass
spectrometry. J Clin Invest 1986; 77: 1601-12. [ Links ]

12. Savage SP, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid
and homocysteine determinations for diagnosing cobalamin and folate deficiencies. Am J Med
1994; 96 (3): 239-46. [ Links ]

13. Magera MJ, Helgeson JK, Matern D, Rinaldo P. Methylmalonic acid measured in plasma
and urine by stable-isotope dilution and electrospray tandem mass spectrometry. Clin Chem
2000; 46 (11): 1804-10. [ Links ]

14. Diaz ML, Linares V. Evaluation of vitamin B12 state and folate. Hematología 2015; 19(3):
264-5. [ Links ]

15. Das KC, Manusselis C, Herbert V. Determination of vitamin B12 (cobalamin) in serum and
erytrocytes by radioassay, and of holo-transcobalamin II (holo-TC II) and holo-haptocorrin (holo-
TC I and III) in serum by adsorbing holo-TC II on microfine silica. J Nut Bio Aug 1991; 2 (8):
455-64. [ Links ]

16. Inserto Kit de Radioensayo SimulTRAC-S Vitamina B12 [57Co]/Folato [125I], ICN
Pharmaceuticals Inc. Diagnostic Division. [ Links ]

17. Miller JW, Garrod HG, Rockwood AL, Kushnir MM, Allen LH, Haan MN, et al. Measurement
of vitamin B12 and holo-transcobalamin, singly and in combination in screening for metabolic
vitamin B12 deficiency. Clin Chem 2006; 52 (2): 278-85. [ Links ]

18. Golding PH. Holo-transcobalamin (Holo-TC, Active-B12) and Herbert´s model for the
development of vitamin B12 deficiency, a review and alternative hypotesis Published online
Springerplus 2016; 5 (1): 668. Available from
URL: springerplus.springeropen.com/articles/10.1186/s40064-016-2252-z. Fecha de acceso 20
de mayo de 2016. [ Links ]

Recibido: 30 de julio de 2016

Aceptado: 15 de julio de 2017

Todo el contenido de esta revista, excepto dónde está identificado,

está bajo una Licencia Creative Commons
 Calle 6 - No. 1344
(B1900TFM) La Plata - Prov. de Buenos Aires - República Argentina
Tel./Fax: (54) (221) 483-8821/483-7281/423-0252/423-3597

4 articulo
REFERENCIAS BIBLIOGRÁFICAS

1. De la Cruz P. Aprovechamiento integral y racional de la tara Caesalpinia spinosa

- Caesalpinia tinctoria. Rev Inst Inv FIGMMG-UNMSM. 2004;7(14):64–
73. [ Links ]

2. Aguilar-Galvez A, Noratto G, Chambi F, Debaste F, Campos D. Potential of tara

(Caesalpinia spinosa) gallotannins and hydrolysates as natural antibacterial
compounds. Food Chem. 2014;156:301-4. doi:
10.1016/j.foodchem.2014.01.110. [ Links ]

3. Avilés R, Carrión J, Huamán J, Bravo M, Rivera D, Rojas N. Actividad

antioxidante, polifenoles totales y contenido de taninos de extractos de tara,
Caesalpinia spinosa. Rev Per Quím Ing Quím. 2010;13:5-11. [ Links ]

4. López A, Oré R, Miranda C, Trabucco J, Orihuela D, Linares J, y col. Capacidad

antioxidante de poblaciones silvestres de "tara" (Caesalpinia spinosa) de las
localidades de Picoy y Santa Fe (Provincia de Tarma , departamento de Junín). Sci
Agropecu. 2011;2:25–9. [ Links ]

5. Chia A, Basilio J, Azurin J, Quispe L, Veramendi L, Villa N. Efecto del pre-

tratamiento con un extracto de Caesalpinia spinosa ante lesiones en mucosa
gástrica inducidas con ácido acetil salicílico en ratas Holtzman. CIMEL.
2013;18(1):30-5. [ Links ]

6. Young V, Kormos W, Chick D, Goroll A. Blueprints Medicine. 5a ed. Philadelphia:

Lippincott William & Wilkins; 2010. 181-2 p. [ Links ]

7. Fernández CJ. Incidencia actual de la gastritis: una breve revisión. Rev CENIC
Ciencias Biológicas. 2014;45(1):10-7. [ Links ]

8. González M, Ordóñez A, Feliu J, Zamora P, Espinosa E. Tratado de medicina

paliativa y tratamiento de soporte del paciente con cáncer. 2a ed. Madrid: Médica
Panamericana. 2007:506-8. [ Links ]

9. Sandoval M, Tenorio J, Tinco A, Loli R, Calderón S. Efecto antioxidante y

citoprotector del tocosh Solanum tuberosum "papa" en la mucosa gástrica de
animales de experimentación. An Fac med. 2015;76(1):15-20.
doi:10.15381/anales. v76i1.11070. [ Links ]

10. Lock O. Investigación Fitoquímica, Métodos en el Estudio de Productos

Naturales. Lima: Segunda edición. Editorial Fondo. Pontificia Universidad Católica
del Perú; 1994.

11. Oré Sifuentes MR. Efectos hipolipémico y antioxidante de Lepidium meyenii

Walp en ratas. (Tesis Doctoral). Lima, Perú: Universidad Nacional Mayor de San
Marcos, 2008: 104 pp. [ Links ]
12. Robert A, Nezamis J, Lancaster C, Hanchar A. Cytoprotection by prostaglandins
in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic
NaCl, and thermal injury. Gastroenterology. 1979;77(3):433-43. [ Links ]

13. Júnior F, Oliveira D, Augusti A, Linde M, Paul J, Echeverria G, y col. Protective

effects of Croton campestris A . St-Hill in different ulcer models in rodents :
Evidence for the involvement of nitric oxide and prostaglandins. J Ethnopharmacol.
2014;153(2):469-77. doi: 10.1016/j. jep.2014.03.005 [ Links ]

14. Sandoval M, Huamán O, Oré R, Loli A, Ayala S. Efecto antioxidante y

citoprotector del Solanum tuberosum (papa) en la mucosa gástrica de animales de
experimentación. An Fac med. 2010;71(3):147-52. [ Links ]

15. Bate-Smith EC. Haemanalysis of tannins: The concept of relative astringency.

Phytochemistry. 1973;12:907-12. [ Links ]

16. Calixto M. Plantas medicinales utilizadas en odontología (Parte I). Kiru.

2006;3(2):80-5. [ Links ]

17. Bussmann R, Malca G, Glenn A, Sharon D, Nilsen B, Parris B, y col. Toxicity of

medicinal plants used in traditional medicine in Northern Peru. J Ethnopharmacol.
2011;137(1):121-40. doi: 10.1016/j. jep.2011.04.071. [ Links ]

18. Zhang L, Lin Y. Tannins from Canarium album with potent antioxidant activity. J
Zhejiang Univ Sci B. 2008;9(5):407-15. [ Links ]

19. Gülçin İ, Huyut Z, Elmastaş M, Aboul-Enein HY. Radical scavenging and

antioxidant activity of tannic acid. Arab J Chem. 2010;3(1):43-53.

20. Valero Y, Colina J, Ineichen E. Efecto del procesamiento sobre la capacidad

antioxidante de la ciruela criolla (Prunus domestica). Arch Latinoam Nutr.
2012;62(4):363–9. [ Links ]

21. Gomes de Melo J, De Sousa Araújo T, Thijan Nobre de Almeida V, Lyra de

Vasconcelos Cabral D, Do Desterro Rodrigues M, Carneiro do Nascimento S, y col.
Antiproliferative activity, antioxidant capacity and tannin content in plants of semi-
arid northeastern Brazil. Molecules. 2010;15(12):8534-42. [ Links ]

22. Doroteo VH, Terry C, Díaz C. Compuestos fenólicos y actividades antioxidante,

antielastasa , anticolagenasa y fotoprotectora in vitro de Myrciaria dubia (camu
camu) y Caesalpinia spinosa (tara) phenolic compounds and antioxidant,
antielastase, anticollagenase and photoprotecti. Rev Soc Quím Perú.
2012;78(4):254-63. [ Links ]

23. Flores F, Briones L. Influencia del material parental y zonas de vida en el

contenido de taninos en Caesalpinia spinosa L(Mol.) Kuntze. FIAT LUX.
2011;7(1):13-9. [ Links ]

24. Melo Ferrari M, Glorio P, Tarazona G. Efecto de la madurez en los componentes

de valor comercial (taninos y goma) de tara Caesalpinia spinosa (Molina ) Kuntze.
Rev Soc Quím Perú. 2013;79(3):218–28. [ Links ]

25. Akuodor G, Essien A, Chilaka K, Akpan J, Ezeokpo B, Ezeonwumelu J.

Gastroprotective effect of the aqueous leaf extract of Guiera senegalensis in albino
rats. Asian Pac J Trop Med. 2013;6(10):771-5. doi: 10.1016/S1995-
7645(13)60136-4. [ Links ]

26. Vasconcelos P, Andreo M, Vilegas W, Hiruma C, Pellizzon C. Effect of Mouriri

pusa tannins and flavonoids on prevention and treatment against experimental
gastric ulcer. J Ethnopharmacol. 2010;131(1):146-53. doi: 10.1016/j.
jep.2010.06.017. [ Links ]

27. Tarnawski A. Mecanismos celulares y moleculares de la mucosa gástrica: La

injuria a la mucosa y la acción protectora de los antiácidos. Rev Gastroenterol del
Perú. 1995;15(1).

28. Tarnawski A, Ahluwalia A, Jones M. Increased susceptibility of aging gastric

mucosa to injury: the mechanisms and clinical implications. World J Gastroenterol.
2014;20(16):4467–82. doi: 10.3748/ wjg.v20.i16.4467 [ Links ]

29. Adewoye EO, Salami AT. Anti-ulcerogenic mechanism of magnesium in

indomethacin induced gastric ulcer in rats. Niger J Physiol Sci. 2013;28:193–
9. [ Links ]

Correspondencia

Miguel Sandoval Vegas [email protected]

El contenido del manuscrito no ha sido publicado previamente.

Fuente de financiamiento: Autofinanciado, con el apoyo de las instalaciones,

equipos y algunos reactivos del Centro de Investigación de Bioquímica y Nutrición
"Alberto Guzmán Barrón" de la Facultad de Medicina de la UNMSM.

Ningún conflicto de interes.

Recibido, 14 junio 2016

Evaluado, 28 setiembre 2016

Aceptado, 8 octubre 2016